We are pleased to announce that we have completed our initial public offering in the Tokyo Stock Exchange Growth market on June 27rd , 2023.
We would like to express our sincere gratitude for your past and future support, and would like to provide our utmost effort in enhancing our shareholder value.

Our firm (Cuorips, Inc.) was established in March 2017 to develop and commercialize Dr. Yoshiki Sawa’s (our Chief Technology Officer as well as Professor Emeritus of Osaka University) technology concerning iPSC derived cardiomyocyte patches.

As you may be well aware, heart failure is the second largest cause of death in Japan and the largest in both U.S. and Europe. Through our commercialization of the above-mentioned patches, we sincerely hope that we could provide cure in the area of severe heart failure and through our regenerative therapies, we hope that we could contribute to the improvement of quality of line for patients not only in Japan but throughout the world.

We are constantly striving to create a firm which can suffice the needs of our stakeholders,
including our investors, employees, patients, etc. We hope that your continuous support and your input can enhance this endeavor.

Thank you once again for your past and future support.

Chief Executive Officer
Cuorips, Inc.
Takayuki Kusanagi